Here’s how Covid-19 has affected funding, development in infectious diseases

“Everybody’s an infectious disease company now,” ARCH Venture Partners Managing Director Bob Nelsen said. By contrast, a report last year showed a huge decline in venture capital investment in the infectious disease space.

Glympse Bio raises more than $46M in Series B round for biosensor technology

graphic design of a liver

The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for the disease.